Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MDWD 
Mediwound Ltd (MDWD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: MDWD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.67
1 Year Target Price $30.67
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.31% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 235.02M USD | Price to earnings Ratio - | 1Y Target Price 30.67 |
Price to earnings Ratio - | 1Y Target Price 30.67 | ||
Volume (30-day avg) 6 | Beta 0.28 | 52 Weeks Range 14.14 - 22.50 | Updated Date 11/1/2025 |
52 Weeks Range 14.14 - 22.50 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -142.18% | Operating Margin (TTM) -100.14% |
Management Effectiveness
Return on Assets (TTM) -22.25% | Return on Equity (TTM) -148.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 194495861 | Price to Sales(TTM) 11.83 |
Enterprise Value 194495861 | Price to Sales(TTM) 11.83 | ||
Enterprise Value to Revenue 9.79 | Enterprise Value to EBITDA -6.32 | Shares Outstanding 12821433 | Shares Floating 8241336 |
Shares Outstanding 12821433 | Shares Floating 8241336 | ||
Percent Insiders 15.14 | Percent Institutions 45.7 |
Upturn AI SWOT
Mediwound Ltd
Company Overview
History and Background
MediWound Ltd. was founded in 2000. It is a biopharmaceutical company focused on developing, manufacturing, and commercializing novel, cost-effective, biopharmaceutical solutions for tissue repair and regeneration.
Core Business Areas
- EscharExu00ae (NexoBridu00ae): A topically applied enzymatic debridement product for removing non-viable burn tissue (eschar) in adults. It is marketed globally by various partners, including Vericel in North America.
- EscharExu00ae (NexoBridu00ae) - Pediatric indication: EscharEx Pediatric indication expands the use to children.
- MW005: A biological product candidate for the treatment of chronic wounds.
Leadership and Structure
The leadership team includes Gal Cohen (CEO), Sharon Malka (CFO) and Boaz Avidor (Chairman). The company is structured around research & development, manufacturing, commercial operations, and clinical development.
Top Products and Market Share
Key Offerings
- EscharExu00ae (NexoBridu00ae): Enzymatic debridement product for burn patients, rapidly removing non-viable tissue. Competitors include surgical debridement, autolytic debridement (ointments), and sharp debridement. Revenue data and market share specific to NexoBrid vary regionally depending on distribution agreements. Vericel (VCEL) is the key competitor in the US.
- MW005: A biological product candidate in development for chronic wound treatment. Competitors include other biologics, advanced wound dressings, and growth factors. Market share data not yet available as the product is in clinical development.
Market Dynamics
Industry Overview
The advanced wound care market is growing, driven by an aging population, rising incidence of diabetes, and increasing awareness of advanced wound care products. The burn care market is also substantial, with a need for faster and more effective debridement methods.
Positioning
MediWound is positioned as a leader in enzymatic debridement, with NexoBrid offering a potentially faster and less invasive alternative to traditional surgical methods. Their pipeline product, MW005, is targeting the chronic wound market.
Total Addressable Market (TAM)
The total addressable market for advanced wound care and burn care is estimated to be in the billions of dollars. MediWound is positioned to capture a portion of this market with its innovative products. Specific figures vary depending on geography and product segment, but the TAM for enzymatic debridement is significant, potentially several hundred million USD.
Upturn SWOT Analysis
Strengths
- Novel enzymatic debridement technology
- Potential to reduce the need for surgical debridement
- Strategic partnerships for global commercialization
- Strong intellectual property portfolio
Weaknesses
- Reliance on partners for sales and marketing
- Regulatory approval hurdles in different geographies
- Potential for competition from new debridement technologies
- History of losses; profitability not yet established.
Opportunities
- Expansion into new geographic markets
- Development of new applications for existing products
- Acquisition or in-licensing of complementary technologies
- Gaining market share from traditional methods
Threats
- Competition from established wound care companies
- Changes in reimbursement policies
- Clinical trial failures
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- VCEL
- SMITH
- BSX
- ABMD
- MTRX
Competitive Landscape
MediWound's NexoBrid offers a potentially faster and less invasive method compared to traditional surgical debridement (Smith & Nephew, Boston Scientific). However, MediWound faces competition from advanced wound dressings and other biologic therapies for chronic wounds. MediWound's advantage lies in its specific enzymatic debridement technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by regulatory approvals and commercial launches of NexoBrid in different regions.
Future Projections: Future growth is projected to come from increased adoption of NexoBrid, expansion into new markets, and the potential launch of MW005.
Recent Initiatives: Recent initiatives include securing new distribution agreements, expanding clinical trials for NexoBrid, and advancing the development of MW005.
Summary
MediWound focuses on enzymatic debridement. NexoBrid's commercialization through partnerships drives growth but also reliance. Advancing MW005 is crucial. Competition, regulatory hurdles, and consistent funding are key considerations for sustainability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- MediWound Ltd. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company presentations
- Industry Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change and may not be accurate. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mediwound Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-03-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 111 | Website https://www.mediwound.com |
Full time employees 111 | Website https://www.mediwound.com | ||
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.